Company intelligence / Profile preview

Sensible Diagnostics

Los Angeles, California, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Sensible Diagnostics developed a real-time PCR point-of-care platform to deliver lab-grade results within 10 minutes for infectious disease diagnostics; its primary multiplexed panel includes flu, COVID-19, and strep throat, with further R&D in oral microbiome and STI testing. No clinical trial data is available and devices/tests are not FDA cleared for marketing[1][2][4].

Therapeutic areas: OtherInfectious Diseases
Modalities: Device
Industry: Molecular Diagnostics

Partnerships

Rapid Acceleration of Diagnostics (RADx) Tech program (National Institutes of Health)[1]Curative (spin-out origin)[1][4]

Beyond the preview

Go deeper on Sensible Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensible Diagnostics.

Explore the full profile